ReviewExpert review of anti-infective therapy2012
Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.
Review in Expert review of anti-infective therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Metabolic Rewiring ofMetabolites · 2024Review
- Repurposing an Antioxidant to KillBiomolecules · 2023Article
- Recent advances in the synthesis of new benzothiazole based anti-tubercular compounds.RSC advances · 2023Review
- Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line.Genetics and molecular biology · 2023Article
- RTP4, a Biomarker Associated with Diagnosing Pulmonary Tuberculosis and Pan-Cancer Analysis.Mediators of inflammation · 2023Article
- Label-Free Comparative Proteomics of Differentially ExpressedPathogens (Basel, Switzerland) · 2021Article
- The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates.Antimicrobial agents and chemotherapy · 2021Article
- Application of Computational Methods in Understanding Mutations inFrontiers in molecular biosciences · 2021Review
- New insights into ethionamide metabolism: influence of oxidized methionine on its degradation path.RSC medicinal chemistry · 2020Article
- Addressing the Challenges of Tuberculosis: A Brief Historical Account.Frontiers in pharmacology · 2017Review
- Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates.Scientific reports · 2016Article
- Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs.PLoS pathogens · 2016Article
- Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.Antimicrobial agents and chemotherapy · 2015Review
- Counterattacking drug-resistant tuberculosis: molecular strategies and future directions.Expert review of anti-infective therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Antifolates inhibit de novo folate biosynthesis, whereas ethionamide targets the mycolate synthetic pathway in Mycobacterium tuberculosis. These antibiotics are effective against M. tuberculosis but their use has been hampered by concerns over toxicity and low therapeutic indexes. With the increasing spread of drug-resistant forms, interest in using old drugs for tuberculosis treatment has been renewed. Specific inhibitors targeting resistance mechanisms could sensitize M. tuberculosis to these available, clinically approved drugs. This review discusses recently developed strategies to boost the antituberculous activity of ethionamide and antifolates. These approaches might help broaden the currently limited chemotherapeutic options of not only drug-resistant but also drug-susceptible tuberculosis, which still remains one of the most common infectious diseases in the developing world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.